Reading Time: 6 minutes My name is Stephanie Shepheard, and I am a Research Associate in the Motor Neuron Disease & Neurotrophic Research Laboratory (MND&NR Lab), Flinders Health & Medicine Research Institute in the College of Medicine & Public Health at Flinders University, South Australia. I measure biological changes, or biomarkers, that may tell us something useful about motor…
Reading Time: 4 minutes Recently published results from the open-label Lighthouse trial investigating safety of the drug Triumeq in people with MND revealed the treatment was safe and ready to progress to a larger Phase 3 clinical trial. The trial was held in Australia and recruited 40 people with MND who all received the active drug; this was because…
Reading Time: 8 minutes Following on from our previous catch-up blog on clinical management talks presented at the Symposium, here is a continuation that looks at talks focusing on treatment therapies and causes of MND. RNA Binding & Transport RNA is the lesser-known ‘cousin’ of DNA – it contains copies of genetic instructions sent out from the nucleus –…
Reading Time: 3 minutes There is recent evidence to suggest that Human Endogenous Retroviruses (HERVs) may be involved in amyotrophic lateral sclerosis (ALS). HERV-K has been directly linked to motor neurone damage and has been found in the brain tissue of patients with ALS. The MND Association recently awarded a small grant to fund part of the ‘Lighthouse Project’…
Reading Time: 3 minutes Researchers from the Flinders University, Australia and University of Miami have discovered a new protein that can act as a biomarker to track disease progression in people with MND. A paper written under the leadership of Dr Shepheard and Dr Rogers was published today in the research journal ‘Neurology’. What is p75 and what do…
